Oramed Pharmaceuticals Inc.

NasdaqCM ORMP

Oramed Pharmaceuticals Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Oramed Pharmaceuticals Inc. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.

Oramed Pharmaceuticals Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -26.76 M, a -26.33% change year over year.
Oramed Pharmaceuticals Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending August 31, 2021 was USD -21.18 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: ORMP

Oramed Pharmaceuticals Inc.

CEO	Mr. Nadav Kidron Esq.
IPO Date	May 1, 2007
Location	United States
Headquarters	1185 Avenue of the Americas
Employees	13
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pet Food Snack Foods Vaccines

Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Key trends

Past 5 years